Clinical trials: Hematological Disease
Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Philadelphia chromosome (BCR-ABL1, Ph) is the most common genetic abnormality in acute lymphoblastic leukemia (ALL) and an independent prognostic risk factor.
- Trial name
- NCT04375683
- Testing
- Flumatinib
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Zhongda Hospital
Joint Bleed, Hemophilia A
Handheld Ultrasound (HHUS) for Home Use in Hemophilia
This is a study in 3 phases that will assess the feasibility and utility of handheld home ultrasound (HHUS) in a patient's home to assess whether a painful episode in the elbow, knee or ankle is a bleed or not.
- Trial name
- HHUS (NCT04131920)
- Testing
- handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington Institute for Coagulation
Myelodysplastic Syndrome
A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests luspatercep with or without epoetin alfa or emavusertib for the treatment of low risk myelodysplasia and anemia.
- Trial name
- NCT07463820
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Emavusertib
- Volunteers
- 270 people
- Sponsor
- National Cancer Institute (NCI)
Severe Aplastic Anemia
The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
Hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA) -matched donor is an effective option for severe aplastic anemia (SAA), but there is no standardized and recommended conditioning regimen.
- Trial name
- NCT06069180
- Testing
- Busulfan, Flu/Cy/ATG or Cy/ATG
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University People's Hospital
Hodgkin Disease, Lymphoma, Non-Hodgkin
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Trial name
- NCT00275262
- Testing
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
Hereditary Haemorrhagic Telangiectasia (HHT)
Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia
Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations.
- Trial name
- NCT02690246
- Testing
- questionnaire
- Where
- Germany
- Volunteers
- 915 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Myeloid Leukemia
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
This study will describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia (CML) used in a real world clinical practice setting.
- Trial name
- NCT05363488
- Testing
- Bosutinib
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Pfizer
Sickle Cell Disease
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD).
- Trial name
- ViSionSerenity (NCT04817670)
- Testing
- VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 25 people
- Sponsor
- Vifor (International) Inc.
Eosinophilic Esophagitis (EoE)
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
This is a randomized, placebo-controlled, parallel-arm, dose-ranging study in subjects with eosinophilic esophagitis, 2-18 years of age. Eligible subjects will be randomized into one of four treatment groups.
- Trial name
- NCT00762073
- Testing
- budesonide
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Shire
Anemia, Sickle Cell
Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes.
- Trial name
- Arginine (NCT00513617)
- Testing
- Arginine
- Where
- 17 sites in United States
- Volunteers
- 128 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding…
- Conditions
- B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03479268
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Hematologic Neoplasms
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
It is hypothesized that a strategy using prophylactic oral Tranexamic Acid (TXA) with therapeutic platelet transfusions is safe and effective compared to prophylactic platelet transfusions in patients undergoing an autologous…
- Trial name
- PATH (NCT02650791)
- Testing
- Tranexamic Acid
- Where
- 5 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Leukemia
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00070174
- Testing
- asparaginase, busulfan, cyclophosphamide
- Where
- 148 sites in United States, Australia and 3 more
- Volunteers
- 350 people
- Sponsor
- Children's Oncology Group
Congenital Hemophilia A
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A
This is an international, multicenter, open-label study to assess the efficacy, safety, and pharmacokinetic (PK) profile of rVIII-SingleChain in pediatric patients with severe hemophilia A.
- Trial name
- NCT02093897
- Testing
- rVIII-SingleChain
- Where
- 37 sites in United States, Australia and 17 more
- Volunteers
- 84 people
- Sponsor
- CSL Behring
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
The purpose of this study is to determine the maximum tolerated dose (MTD), safety and toxicity when cyclophosphamide, rituximab and lenalidomide (Revlimid) are combined for the treatment of relapsed/refractory of chronic…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
- Trial name
- NCT01005979
- Testing
- Lenalidomide, Rituximab, and Cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Multiple Myeloma, Renal Failure
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed…
- Trial name
- NCT06142396
- Testing
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Augusta University
Myelodysplastic Syndrome, Acute Myeloid Leukemia
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
- Trial name
- NCT00774046
- Testing
- Ara-C, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Leukemia
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006390
- Testing
- alemtuzumab, filgrastim, cyclophosphamide
- Where
- 14 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
Bortezomib was an important drug in the treatment of multiple myeloma (MM),and peripheral neuropathy (PN) is a significant dose-limiting toxicity of bortezomib that typically occurs within the first courses of bortezomib, reaches…
- Trial name
- NCT02093910
- Testing
- Monosialotetrahexosylganglioside
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.